Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Transcription factors are believed to have a dominant role in acute myeloid leukemia (AML). This idea is supported by analysis of gene-knockout mice, which uncovered crucial roles of several transcription factors in normal hematopoiesis, and of individuals with leukemia, in whom transcription factors are frequently downregulated or mutated. However, analysis of knockout animals has not shown a direct link between abrogated transcription factors and the pathogenesis of AML. Sfpi1, encoding the lineage-specific transcription factor PU.1, is indispensable for normal myeloid and lymphoid development. We found that mice carrying hypomorphic Sfpi1 alleles that reduce PU.1 expression to 20% of normal levels, unlike mice carrying homo- or heterozygous deletions of Sfpi1, developed AML. Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. Malignant transformation was associated with a high frequency of clonal chromosomal changes. Retroviral restoration of PU.1 expression rescued myeloid differentiation of mutant progenitors and AML blasts. These results suggest that tightly graded reduction, rather than complete loss, of a lineage-indispensable transcription factor can induce AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preleukemic states (e.g., MDS), where PU.1 downregulation permits clonal expansion 33-35”
From USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization (2026) · cites this paper as [33]
In the citing paper
“In mice, a decrease in Pu.1-mediated differentiation gene activation causes leukemia.22”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [22]
In the citing paper
“Studies in murine models of AML with decreased levels of PU.1 showed an elevated expression of c-Myc.28”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“A reduction in PU.1 expression and activity is commonly seen in mouse and human cases of AML.[28][29][30]”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [28]
In the citing paper
“Although loss or near-complete loss of the hematopoietic transcription factor PU.1 induces acute myeloid leukemia (AML) in mice”
From Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia (2015) · cites this paper as [9]
19 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We could not separate mutant progenitors into distinct common myeloid progenitor, myeloid-erythroid progenitor and granulocyte-macrophage progenitor subpopulation”
BackgroundSelf-citationOkuda, T., van Deursen, J., Hiebert, S. W., Grosveld, G., & Downing, J. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80986-1 · Cited by 1,856 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundThe c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., & Brinster, R. L. (1985) · Nature · doi:10.1038/318533a0 · Cited by 1,779
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289 · cited 1×
“F331 Spleen 39,X,-Y[6]/40,idem,+15[2]/41,XY,+15[2]”
Targeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130
An Fgf8 mutant allelic series generated by Cre- and Flp-mediated recombination
Meyers, E. N., Lewandoski, M., & Martin, G. R. (1998) · Nature Genetics · doi:10.1038/ng0298-136 · Cited by 1,031 · cited 1×
“We released a FRT -PGK neo - FRT resistance cassette from pK-11 (ref”
MethodZhang, D.-E., Zhang, P., Wang, N.-D., Hetherington, C. J., Darlington, G. J., & Tenen, D. G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.569 · Cited by 910 · cited 1×
“Like mice deficient in other transcription factors implicated in human AM”
BackgroundSelf-citationPabst, T., Mueller, B. U., Zhang, P., Radomska, H. S., Narravula, S., Schnittger, S., Behre, G., Hiddemann, W., & Tenen, D. G. (2001) · Nature Genetics · doi:10.1038/85820 · Cited by 901
Self-citationReversible Tumorigenesis by MYC in Hematopoietic Lineages
Felsher, D. W., & Bishop, J. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80367-6 · Cited by 881
Research works printed but not linked: 2
- Iwasaki-Arai, J. et al. C/EBPα deficiency in hematopoiesis induces accumulation of non-malignant myeloblasts mimicking acute myelogenous leukemia. Blood 100, 61a (2002).
- Duprez, E. et al. PU.1 deficiency blocks the production of Common Myeloid and Common Lymphoid Progenitors in both adult and fetal liver myelopoiesis. Blood 100, 61a (2002).
Cited by
Items 101–200 of 518
Signal Transduction of Oncogenic Flt3
Choudhary, C., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05090 · Cited by 101
“Imbalanced expression or impairments in the function of these transcription factors by mutations result in a block of differentiation [91,92].”
BackgroundTranscriptional Control of Natural Killer Cell Development and Function
Hesslein, D. G. T., & Lanier, L. L. (2011) · Advances in immunology · doi:10.1016/b978-0-12-387664-5.00002-9 · Cited by 97
“PU.1 also functions as a tumor suppressor, as the absence or reduction of PU.1 results in the induction of acute myeloid leukemia (Metcalf et al., 2006; Mueller et al., 2006; Rosenbauer et al., 2004).”
BackgroundC/EBPα directs monocytic commitment of primary myeloid progenitors
Wang, D., D'Costa, J., Civin, C. I., & Friedman, A. D. (2006) · Blood · doi:10.1182/blood-2005-12-008763 · Cited by 84
Melo-Cardenas, J., Xu, Y., Wei, J., Tan, C., Kong, S., Gao, B., Montauti, E., Kirsammer, G., Licht, J. D., Yu, J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811760 · Cited by 84
Cui, W., Kong, N. R., Ma, Y., Amin, H. M., Lai, R. L., & Chai, L. (2006) · Modern Pathology · doi:10.1038/modpathol.3800694 · Cited by 92
Walter, M. J., Park, J. S., Ries, R. E., Lau, S. K. M., McLellan, M., Jaeger, S., Wilson, R. K., Mardis, E. R., & Ley, T. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504247102 · Cited by 83
Positive and negative regulators of the metallothionein gene (Review)
Takahashi, S. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3459 · Cited by 82
PU.1 and Haematopoietic Cell Fate: Dosage Matters
Mak, K. S., Funnell, A. P. W., Pearson, R. C. M., & Crossley, M. (2011) · International Journal of Cell Biology · doi:10.1155/2011/808524 · Cited by 77
“1 expression by 80% in mice and results in acute myeloid leukaemia (AML) and T-cell lymphoma [10, 13].”
BackgroundPundhir, S., Bratt Lauridsen, F. K., Schuster, M. B., Jakobsen, J. S., Ge, Y., Schoof, E. M., Rapin, N., Waage, J., Hasemann, M. S., & Porse, B. T. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.012 · Cited by 77
“Spi1 expression is to a large extent controlled by a 14 kb enhancer, which in mice reduces the levels of PU.1 by 80% upon deletion (Rosenbauer et al., 2004).”
BackgroundTissue, cell and stage specificity of (epi)mutations in cancers
Sieber, O. M., Tomlinson, S. R., & Tomlinson, I. P. M. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1674 · Cited by 77
“1 levels to 20% and developed an aggressive form of AM”
BackgroundBarth, J., Abou‐El‐Ardat, K., Dalic, D., Kurrle, N., Maier, A., Mohr, S., Schütte, J., Vaßen, L., Greve, G., Schulz‐Fincke, J., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0375-7 · Cited by 79
Sokalski, K. M., Li, S. K. H., Welch, I., Cadieux-Pitre, H.-A. T., Gruca, M. R., & DeKoter, R. P. (2011) · Blood · doi:10.1182/blood-2011-02-335539 · Cited by 73
“1 expression has been associated with AML in human patients,(29,30) and is sufficient to induce AML in mouse models.(31,32) There are several reports of reduced PU.”
BackgroundGupta, P., Gurudutta, G. U., Saluja, D., & Tripathi, R. P. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00757.x · Cited by 74
“1 expression in the bone marrow was decreased to 20% of wild-type levels all develop a block in macrophage and B-cell development, genomic instability and AML [13].”
BackgroundA comprehensive profile of ChIP-Seq-based PU.1/Spi1 target genes in microglia.
Satoh, J.-I., Asahina, N., Kitano, S., & Kino, Y. (2014) · Gene Regulation and Systems Biology · doi:10.4137/grsb.s19711 · Cited by 74
NF-κB p50 Regulates C/EBPα Expression and Inflammatory Cytokine-Induced Neutrophil Production
Wang, D., Paz‐Priel, I., & Friedman, A. D. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803861 · Cited by 82
“1 levels due to deletion of a distal enhancer, have greatly reduced monopoiesis (30).”
BackgroundRole of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
“Second, in situ deletion of the URE in mice by homologous recombination led to a decrease in PU.1 expression to approximately 20% of wild-type levels in multiple hematopoietic lineages [ 48 ].”
BackgroundInfluentialSelf-citationC/EBPα induces PU.1 and interacts with AP-1 and NF-κB to regulate myeloid development
Friedman, A. D. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.010 · Cited by 86
“1 distal enhancer results in loss of monopoiesis with preservation of granulopoiesis [13]; and deletion of PU.”
BackgroundIs PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis?
Dakic, A., Wu, L., & Nutt, S. L. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.01.006 · Cited by 72
Cangemi, R., Mensah, A. A., Albertini, V., Jain, A., Grand, M. M., Chiorino, G., Catapano, C. V., & Carbone, G. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210953 · Cited by 81
“1 fail to differentiate, acquire self-renewal capacity and are prone to transformation leading to acute myeloid leukemia (Rosenbauer et al., 2004).”
Bonifer, C. (2008) · Frontiers in Bioscience · doi:10.2741/2700 · Cited by 70
“1 causes an AML in mice which is characterized by the absence of csf1r expression (58).”
BackgroundKatsumoto, T., Yoshida, N., & Kitabayashi, I. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00865.x · Cited by 80
Dissecting the role of aberrant DNA methylation in human leukaemia
Amabile, G., Di Ruscio, A., Müller, F., Welner, R. S., Yang, H., Ebralidze, A. K., Zhang, H., Levantini, E., Qi, L., Martinelli, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms8091 · Cited by 74
“Future studies will be necessary to assess optimal dosage range and scheduling mode to: (1) reduce the toxicity and (2) understand the potential synergic effect of the two drugs (Fig.”
BackgroundSelf-citationDatta, A., Sinha-Datta, U., Dhillon, N. K., Buch, S. J., & Nicot, C. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600684200 · Cited by 86
PU.1 cooperates with IRF4 and IRF8 to suppress pre-B-cell leukemia
Pang, S. H. M., Minnich, M., Gangatirkar, P., Zheng, Z., Ebert, A., Song, G., Dickins, R. A., Corcoran, L. M., Mullighan, C. G., Busslinger, M., et al. (2016) · Leukemia · doi:10.1038/leu.2016.27 · Cited by 69
Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients
Le Coz, C., Nguyen, D. N., Su, C., Nolan, B. E., Albrecht, A. V., Xhani, S., Sun, D., Demaree, B., Pillarisetti, P., Khanna, C., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201750 · Cited by 69
Pandolfi, A., Barreyro, L., & Steidl, U. G. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0109 · Cited by 75
Wallace, J. A., Kagele, D., Eiring, A. M., Kim, C. N., Hu, R., Runtsch, M. C., Alexander, M., Huffaker, T. B., Lee, S.-H., Patel, A. B., et al. (2017) · Blood · doi:10.1182/blood-2016-09-740209 · Cited by 67
“Patient 1 (15-173) Patient 2 (16-119) Patient 3 (17-008) An ne xi n V po si tiv ity”
Wagner, K., Zhang, P., Rosenbauer, F., Drescher, B., Kobayashi, S., Radomska, H. S., Kutok, J. L., Gilliland, D. G., Krauter, J., & Tenen, D. G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508143103 · Cited by 66
Self-citationOncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Moore, S., Shigematsu, H., Ley, T. J., Akashi, K., Beau, M. M. L., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-04-015040 · Cited by 67
Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development
Li, H., Ji, M. H., Klarmann, K. D., & Keller, J. R. (2010) · Blood · doi:10.1182/blood-2009-11-255075 · Cited by 76
RUNX1 regulates corepressor interactions of PU.1
Hu, Z., Gu, X., Baraoidan, K., Ibanez, V., Sharma, A., Kadkol, S., Munker, R., Ackerman, S., Nucifora, G., & Saunthararajah, Y. (2011) · Blood · doi:10.1182/blood-2010-10-312512 · Cited by 63
A RUNX–CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes
Murakami, K., Sasaki, H., Nishiyama, A., Kurotaki, D., Kawase, W., Ban, T., Nakabayashi, J., Kanzaki, S., Sekita, Y., Nakajima, H., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00871-y · Cited by 67
Hoogenkamp, M., Krysinska, H., Ingram, R., Huang, G., Barlow, R., Clarke, D., Ebralidze, A., Zhang, P., Tagoh, H., Cockerill, P. N., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00905-07 · Cited by 63
“pPNT-( 14kb URE)-KI was used as described previously (34).”
BackgroundMethodSelf-citationRIG-I plays a critical role in negatively regulating granulocytic proliferation
Zhang, N.-N., Shen, S.-H., Jiang, L.-J., Zhang, W., Zhang, H.-X., Sun, Y.-P., Li, X.-Y., Huang, Q.-H., Ge, B.-X., Chen, S.-J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804895105 · Cited by 61
Huber, R., Pietsch, D., Günther, J., Welz, B., Vogt, N., & Brand, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1322-4 · Cited by 71
“1 expression by deletion of its distal enhancer [213], or PU.”
BackgroundPang, S. H. M., de Graaf, C. A., Hilton, D. J., Huntington, N. D., Carotta, S., Wu, L., & Nutt, S. L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01264 · Cited by 60
Suraweera, N., Meijne, E., Moody, J., Carvajal-Carmona, L. G., Yoshida, K., Pollard, P., Fitzgibbon, J., Riches, A., van Laar, T., Huiskamp, R., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208422 · Cited by 60
Sweetser, D. A., Peniket, A. J., Haaland, C. M., Blomberg, A. A., Zhang, Y., Zaidi, S. T., Dayyani, F., Zheng, Z. S., Heerema, N. A., Boultwood, J., et al. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20236 · Cited by 64
“This effect was not seen in heterozygotes or in mice with null alleles (Rosenbauer et al., 2004).”
BackgroundHeritable and Lineage-Specific Gene Knockdown in Zebrafish Embryo
Dong, M., Fu, Y., Du, T., Jing, C., Fu, C., Chen, Y., Jin, Y., Deng, M., & Liu, T. X. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006125 · Cited by 61
“haploinsufficiency, contribute to the pathogenesis of myeloid malignancies and tumorigenesis [6,8], the methodology described”
BackgroundMethodMakarem, M., Kannan, N., Nguyen, L. V., Knapp, D. J. H. F., Balani, S., Prater, M. D., Stingl, J., Raouf, A., Nemirovsky, O., Eirew, P. D., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001630 · Cited by 65
“ml CSF-1 [22], and 40 ng/ml HGF [23,24], Figure 4A and C).”
Lopez, C. K., Noguera, E., Stavropoulou, V., Robert, E., Aid, Z., Ballerini, P. F., Bilhou‐Nabera, C., Lapillonne, H., Boudia, F., Thirant, C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1463 · Cited by 64
Hikami, K., Kawasaki, A., Ito, I., Koga, M., Ito, S., Hayashi, T., Matsumoto, I., Tsutsumi, A., Kusaoi, M., Takasaki, Y., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30188 · Cited by 58
“70) Control 160 (36) 217 (48) 73 (16) 0.”
PU.1 controls the expression of long noncoding RNA HOTAIRM1 during granulocytic differentiation
Wei, S., Zhao, M., Wang, X., Li, Y., & Wang, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0274-1 · Cited by 61
“1 can lead to the development of AML [20–22].”
BackgroundCirovic, B., Schönheit, J., Kowenz‐Leutz, E., Ivanovska, J., Klement, C., Pronina, N., Bégay, V., & Leutz, A. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.015 · Cited by 65
“C/EBP Dosage and Granulocyte-Macrophage Lineage Choice Transcription factor dosage is an important determinant in hematopoietic lineage choice (Dahl et al., 2003; DeKoter et al., 2007; DeKoter and Singh, 2000; Di Tullio and Graf, 2012; Ma et al., 2014; Rosenbauer et al., 2004; Simmons et al., 2012).”
BackgroundElagib, K. E., & Goldfarb, A. N. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.010 · Cited by 66
Subramanian, S., Thoms, J. A. I., Huang, Y., Cornejo-Páramo, P., Koch, F. C., Jacquelin, S., Shen, S., Song, E., Joshi, S., Brownlee, C., et al. (2023) · Blood · doi:10.1182/blood.2023021120 · Cited by 57
“…in the MEP model, consistent with known roles for ETS factors such as PU.1 in driving myeloid differentiation, while GATA motifs had positive SHAP values in HSC-MPP and MEP models but negative values in the GMP model, consistent with GATA factors such as GATA1 driving the erythroid lineage 55,56 .”
Ma, O., Hong, S., Guo, H. W., Ghiaur, G., & Friedman, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095784 · Cited by 61
“1 expression favors granulopoiesis over monopoiesis [21–23].”
Jack, G. D., Zhang, L., & Friedman, A. D. (2009) · Blood · doi:10.1182/blood-2008-11-191536 · Cited by 65
Tatetsu, H., Ueno, S., Hata, H., Yamada, Y., Takeya, M., Mitsuya, H., Tenen, D. G., & Okuno, Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4265 · Cited by 51
“1 to 20% of the WT level and subsequent leukemia in mice (9).”
BackgroundSelf-citationLin, L., Pang, W., Chen, K., Wang, F., Gengler, J., Sun, Y., & Tong, Q. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00462.2011 · Cited by 54
“1 in adult mice resulted in the development of myeloid leukemia (46, 58).”
BackgroundAnalysis of concentration-dependent functions of PU.1 in hematopoiesis using mouse models
DeKoter, R. P., Kamath, M. B., & Houston, I. B. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.004 · Cited by 63
“[10] generated mice with a deletion of an upstream regulatory region (ΔURE) in the Sfpi1 gene.”
BackgroundInfluentialWontakal, S. N., Guo, X., Will, B., Shi, M., Raha, D., Mahajan, M. C., Weissman, S., Snyder, M., Steidl, U., Zheng, D., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001392 · Cited by 53
“1 low erythroid progenitors relative to wild-type progenitors (Figure 3C), similar to reports in other cell types [30,32,33].”
BackgroundResultPU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway
Zhou, J., Wu, J., Li, B., Liu, D., Yu, J., Yan, X., Zheng, S., Wang, J., Zhang, L., Zhang, L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.384 · Cited by 53
Self-citationBockamp, E., Sprengel, R., Eshkind, L. G., Lehmann, T. J., Braun, J. M., Emmrich, F., & Hengstler, J. G. (2008) · Regenerative Medicine · doi:10.2217/17460751.3.2.217 · Cited by 61
Zarnegar, M. A., Chen, J., & Rothenberg, E. V. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00354-10 · Cited by 52
“1 expression within hematopoietic cells nor fully blocked T-cell silencing (28, 29).”
BackgroundEVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription
Ayoub, E., Wilson, M. P., McGrath, K. E., Li, A. J., Frisch, B. J., Palis, J., Calvi, L. M., Zhang, Y., & Perkins, A. S. (2018) · Nature Communications · doi:10.1038/s41467-018-06208-y · Cited by 52
Targetable leukaemia dependency on noncanonical PI3Kγ signalling
Luo, Q., Raulston, E. G., Prado, M. A., Wu, X., Gritsman, K., Whalen, K. S., Yan, K., Booth, C. A. G., Xu, R., van Galen, P., et al. (2024) · Nature · doi:10.1038/s41586-024-07410-3 · Cited by 53
Lin, J.-H., Lin, J.-Y., Chou, Y.-C., Chen, M., Yeh, T., Lin, C., Lin, S.-J., & Tsai, C.-H. A. (2015) · Blood · doi:10.1182/blood-2014-08-594689 · Cited by 56
“1 gene in B cells impairs cell differentiation and causes pre–B-cell acute lymphoblastic leukemia.(52) Of interest, the expression of E47 and PU.”
BackgroundEpigenetic regulation of neutrophil development and function
Ostuni, R., Natoli, G., Cassatella, M. A., & Tamassia, N. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.04.002 · Cited by 55
Kurkewich, J. L., Hansen, J. M., Klopfenstein, N., Zhang, H., Wood, C., Boucher, A. C., Hickman, J. W., Muench, D. E., Grimes, H. L., & Dahl, R. E. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006887 · Cited by 54
Verbiest, T., Bouffler, S., Nutt, S. L., & Badie, C. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv016 · Cited by 46
“1 as a suppressor of rAML, Sfpi1ure/ure mice or those resulting from the conditional deletion of the DNA binding Ets domain (exon 5) develop AML (22,37).”
BackgroundH2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia
Kawahara, M., Pandolfi, A., Bartholdy, B., Barreyro, L., Will, B., Roth, M. E., Okoye-Okafor, U. C., Todorova, T. I., Figueroa, M. E., Melnick, A. M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.027 · Cited by 55
“1 gene have been previously described (Rosenbauer et al., 2004).”
Kosmider, O., Denis, N., Lacout, C., Vainchenker, W., Dubreuil, P., & Moreau-Gachelin, F. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.009 · Cited by 49
Erythroleukemia-historical perspectives and recent advances in diagnosis and management
Boddu, P., Benton, C. B., Wang, W., Borthakur, G., Khoury, J. D., & Pemmaraju, N. (2018) · Blood Reviews · doi:10.1016/j.blre.2017.09.002 · Cited by 49
“1 gene expression associate with an increasingly aggressive AML phenotype [53].”
Houston, I. B., Kamath, M. B., Schweitzer, B. L., Chlon, T. M., & DeKoter, R. P. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.04.005 · Cited by 49
Review: genetic models of acute myeloid leukaemia
McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2008) · Oncogene · doi:10.1038/onc.2008.16 · Cited by 57
“Specifically, Sfp1 knockdown mice (Rosenbauer et al., 2004), encoding a lineage-specific transcription factor PU.”
BackgroundIFN Consensus Sequence Binding Protein (Icsbp) Is Critical for Eosinophil Development
Milanovic, M., Terszowski, G., Struck, D., Liesenfeld, O., & Carstanjen, D. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.5045 · Cited by 47
Xu, Y., Schnorrer, P., Proietto, A. I., Kowalski, G. M., Febbraio, M. A., Acha‐Orbea, H., Dickins, R. A., & Villadangos, J. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001934 · Cited by 53
Accelerated Leukemogenesis by Truncated CBFβ-SMMHC Defective in High-Affinity Binding with RUNX1
Kamikubo, Y., Zhao, L., Wunderlich, M., Corpora, T., Hyde, R. K., Paul, T. A., Kundu, M., Garrett, L. J., Compton, S. T., Huang, G., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.022 · Cited by 51
“Mice with homo- or heterozygous dele- tion of Pu.1 do not develop leukemia; on the other hand, mice carrying hypomorphic alleles of Pu.1 with reduced expression (20% of normal) developed AML rapidly and efficiently (Rose- nbauer et al., 2004).”
BackgroundEpigenetic control of hematopoiesis: the PU.1 chromatin connection
van Riel, B., & Rosenbauer, F. (2014) · Biological Chemistry · doi:10.1515/hsz-2014-0195 · Cited by 48
Self-citationPU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells
Yuki, H., Ueno, S., Tatetsu, H., Niiro, H., Iino, T., Endo, S., Kawano, Y., Komohara, Y., Takeya, M., Hata, H., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431429 · Cited by 56
Self-citationCurik, N., Burda, P., Vargová, K., Pospíšil, V., Beličková, M., Vlckova, P., Savvulidi, F. G., Nečas, E., Hajkova, H., Haškovec, C., et al. (2012) · Leukemia · doi:10.1038/leu.2012.47 · Cited by 48
Concise Review: Erythroid Versus Myeloid Lineage Commitment: Regulating the Master Regulators
Wolff, L., & Humeniuk, R. (2013) · Stem Cells · doi:10.1002/stem.1379 · Cited by 41
Targeting transcription factors in acute myeloid leukemia
Takei, H., & Kobayashi, S. S. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2488-1 · Cited by 53
Bruserud, Ø., Stapnes, C., Tronstad, K. J., Ryningen, A., Ånensen, N., & Gjertsen, B. T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.1.51 · Cited by 49
“1 (reduced but not absent) is then important [39,40].”
BackgroundPU.1-c-Jun interaction is crucial for PU.1 function in myeloid development
Zhao, X., Bartholdy, B., Yamamoto, Y., Evans, E. K., Alberich-Jordà, M., Staber, P. B., Benoukraf, T., Zhang, P., Zhang, J., Trinh, B. Q., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03888-7 · Cited by 46
Self-citationYoshida, H., Ichikawa, H., Tagata, Y., Katsumoto, T., Ohnishi, K., Akao, Y., Naoe, T., Pandolfi, P. P., & Kitabayashi, I. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02422-06 · Cited by 45
“1 below a critical level, followed by the induction of myeloid leukemia (26).”
BackgroundGFI1 as a novel prognostic and therapeutic factor for AML/MDS
Hönes, J. M., Botezatu, L., Helness, A., Vadnais, C., Vaßen, L., Robert, F., Hergenhan, S. M., Thivakaran, A., Schütte, J., Al-Matary, Y. S., et al. (2016) · Leukemia · doi:10.1038/leu.2016.11 · Cited by 52
Mouse models for radiation-induced cancers
Rivina, L., Davoren, M. J., & Schiestl, R. H. (2016) · Mutagenesis · doi:10.1093/mutage/gew019 · Cited by 46
“1 in the bone marrow, reducing expression levels to only 20% of wild type, induces AML in mice inactivated from birth by 3–8 months of age (125).”
BackgroundTranscription Factor GFI1B in Health and Disease
Anguita, E., Candel, F. J., Chaparro, A., & Roldán‐Etcheverry, J. J. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00054 · Cited by 47
Pimanda, J. E., Chan, W. Y. I., Wilson, N. K., Smith, A. M., Kinston, S., Knezevic, K., Janes, M. E., Landry, J., Kolb‐Kokocinski, A., Frampton, J., et al. (2008) · Blood · doi:10.1182/blood-2008-05-157560 · Cited by 49
Natural compounds and pharmaceuticals reprogram leukemia cell differentiation pathways
Morceau, F., Chateauvieux, S., Orsini, M., Trécul, A., Dicato, M. A., & Diederich, M. F. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.03.013 · Cited by 46
Jego, G., Lanneau, D., De Thonel, A., Berthenet, K., Hazoumé, A., Droin, N., Hamman, A., Girodon, F., Bellaye, P.-S., Wettstein, G., et al. (2014) · Leukemia · doi:10.1038/leu.2014.63 · Cited by 42
Yu, T., Guo, W., Tian, Y., Xu, J., Chen, J., Li, L., & Wen, Z. (2017) · Blood · doi:10.1182/blood-2016-07-727651 · Cited by 42
“1 regulates specification and maturation of macrophages and neutrophils in a dosage-dependent manner.(21,22) Because PU.”
BackgroundOkumura, A. J., Peterson, L. F., Okumura, F., Boyapati, A., & Zhang, D. (2008) · Blood · doi:10.1182/blood-2007-11-124735 · Cited by 48
PU.1 is regulated by NF-κB through a novel binding site in a 17 kb upstream enhancer element
Bonadies, N., Neururer, C., Steege, A., Vallabhapurapu, S., Pabst, T., & Mueller, B. U. (2009) · Oncogene · doi:10.1038/onc.2009.371 · Cited by 47
“1 expression induces leukemia in mice (Rosenbauer et al., 2004).”
Hematopoietic stem cells and retroviral infection
Banerjee, P., Crawford, L. B., Samuelson, E., & Feuer, G. (2010) · Retrovirology · doi:10.1186/1742-4690-7-8 · Cited by 45
“Tenen DG: Disruption of differentiation in human cancer: AML shows the way.”
BackgroundInfluentialKamath, M. B., Houston, I. B., Janovski, A. J., Zhu, X., Gowrisankar, S., Jegga, A. G., & DeKoter, R. P. (2008) · Leukemia · doi:10.1038/leu.2008.67 · Cited by 41
Stem cell origin of myelodysplastic syndromes
Elias, H. K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A. K., & Steidl, U. G. (2013) · Oncogene · doi:10.1038/onc.2013.520 · Cited by 42
STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells
Schepers, H., Wierenga, A. T. J., Vellenga, E., & Schuringa, J. J. (2012) · JAK-STAT · doi:10.4161/jkst.19316 · Cited by 43
“1, which at 20% expression gives rise to self-renewing murine myeloid leukemias, whereas 50% or 100% reduction in expression do not have such a dramatic effect.(108,109) Recently, also for Wnt signaling it was demonstrated that intermediate activation levels enhance”
Sanchez, P. V., Glantz, S. T., Scotland, S., Kasner, M. T., & Carroll, M. P. (2013) · Leukemia · doi:10.1038/leu.2013.202 · Cited by 41
Genome-wide approach to identify risk factors for therapy-related myeloid leukemia
Bogni, A., Chen, C., Liu, W., Yang, W., Pfeffer, J. R., Mukatira, S., French, D., Downing, J. R., Pui, C., & Relling, M. V. (2005) · Leukemia · doi:10.1038/sj.leu.2404059 · Cited by 39
Smith, A. M., Sánchez, M. J., Follows, G., Kinston, S., Donaldson, I. J., Green, A. R., & Göttgens, B. (2008) · Genome Research · doi:10.1101/gr.077008.108 · Cited by 41
Protein Acetylation Regulates Both PU.1 Transactivation and Igκ 3′ Enhancer Activity
Bai, Y., Srinivasan, L., Perkins, L., & Atchison, M. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.8.5160 · Cited by 39
“1 expression levels in vivo to 20% of wild-type levels leads to a high incidence of acute myeloid leukemia (31).”
BackgroundRoos-Weil, D., Decaudin, C., Armand, M., Della-Valle, V., Diop, M. K., Ghamlouch, H., Ropars, V., Hérate, C., Lara, D., Durot, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0873 · Cited by 38
T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1
Zhu, H., Zhang, L., Wu, Y., Dong, B., Guo, W., Wang, M., Yang, L., Fan, X., Tang, Y., Liu, N., et al. (2018) · eLife · doi:10.7554/elife.38314 · Cited by 42
Stirewalt, D. L., Pogosova‐Agadjanyan, E. L., Tsuchiya, K. D., Joaquin, J., & Meshinchi, S. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.27 · Cited by 38
Spi-1/PU.1 Oncoprotein Affects Splicing Decisions in a Promoter Binding-dependent Manner
Guillouf, C., Gallais, I., & Moreau-Gachelin, F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512049200 · Cited by 30
The Runx-PU.1 pathway preserves normal and AML/ETO9a leukemic stem cells
Staber, P. B., Zhang, P., Ye, M., Welner, R. S., Levantini, E., Di Ruscio, A., Ebralidze, A. K., Bach, C., Zhang, H., Zhang, J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-550855 · Cited by 36
Self-citationGSK-3: a multifaceted player in acute leukemias
Martelli, A. M., Evangelisti, C., Paganelli, F., Chiarini, F., & McCubrey, J. A. (2021) · Leukemia · doi:10.1038/s41375-021-01243-z · Cited by 40
Metadata
- Authors
- Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Dartmouth College (US)
- Corresponding author
- Tenen, Daniel G
- ORCID
- Venue
- Nature Genetics
- Published
- 2004-05-16
- Volume
- 36
- Issue
- 6
- Pages
- 624-630
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2060618743
- Cited by
- 506
- References
- 28
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 11 · 2023: 21 · 2022: 10 · 2021: 25 · 2020: 13 · 2019: 22 · 2018: 25 · 2017: 24 · 2016: 19 · 2015: 18 · 2014: 27 · 2013: 36 · 2012: 28
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Funders
- Dartmouth College
- Deutsche Forschungsgemeinschaft
- National Institutes of Health
- National Cancer Institute (P30CA023108)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- acute myeloid leukemia, PU.1, transcription factors, hypomorphic allele, myeloid development, myeloid differentiation, leukemogenesis
- MeSH terms
- Proto-Oncogene Protein Spi-1, Animals, Bone Marrow, Hematopoiesis, Humans, Karyotyping, Mice, Inbred C57BL, Mice, Mutant Strains, Mice, Transgenic, Proto-Oncogene Proteins, Spleen, Leukemia, Myeloid, Acute, Trans-Activators, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.